Commonwealth Equity Services LLC Has $26.71 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Commonwealth Equity Services LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the 2nd quarter, Holdings Channel reports. The firm owned 346,600 shares of the biopharmaceutical company’s stock after purchasing an additional 5,266 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Gilead Sciences were worth $26,713,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of GILD. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Gilead Sciences by 98,797.6% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock worth $30,366,034,000 after acquiring an additional 393,607,491 shares during the last quarter. FMR LLC increased its holdings in shares of Gilead Sciences by 27.2% in the first quarter. FMR LLC now owns 20,909,082 shares of the biopharmaceutical company’s stock valued at $1,734,826,000 after purchasing an additional 4,470,179 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after purchasing an additional 13,764,169 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Gilead Sciences by 2.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,452,922 shares of the biopharmaceutical company’s stock worth $1,345,097,000 after buying an additional 440,718 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Gilead Sciences by 11.5% during the 4th quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after buying an additional 1,780,489 shares during the period. 82.33% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $75.45 on Monday. The company’s 50 day moving average price is $76.82 and its two-hundred day moving average price is $77.26. The firm has a market capitalization of $94.01 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.00 and a beta of 0.32. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.34 and a quick ratio of 1.20. Gilead Sciences, Inc. has a fifty-two week low of $72.87 and a fifty-two week high of $89.74.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. The business had revenue of $7.05 billion for the quarter, compared to analyst estimates of $6.81 billion. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. Gilead Sciences’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.76 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.75 per share. The ex-dividend date is Thursday, December 14th. This represents a $3.00 annualized dividend and a yield of 3.98%. Gilead Sciences’s dividend payout ratio is presently 64.38%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GILD shares. Barclays reduced their price objective on Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, July 24th. Piper Sandler reduced their target price on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, July 24th. StockNews.com started coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They issued a “strong-buy” rating on the stock. UBS Group dropped their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating for the company in a research note on Wednesday, November 8th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 9th. They set a “hold” rating and a $75.00 target price on the stock. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $88.22.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief financial officer now owns 104,003 shares of the company’s stock, valued at $8,320,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the sale, the insider now owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief financial officer now owns 104,003 shares in the company, valued at approximately $8,320,240. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.